AU2002362098A1 - Methods of therapy for non-hodgkin's lymphoma - Google Patents

Methods of therapy for non-hodgkin's lymphoma

Info

Publication number
AU2002362098A1
AU2002362098A1 AU2002362098A AU2002362098A AU2002362098A1 AU 2002362098 A1 AU2002362098 A1 AU 2002362098A1 AU 2002362098 A AU2002362098 A AU 2002362098A AU 2002362098 A AU2002362098 A AU 2002362098A AU 2002362098 A1 AU2002362098 A1 AU 2002362098A1
Authority
AU
Australia
Prior art keywords
hodgkin
lymphoma
therapy
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002362098A
Other versions
AU2002362098A8 (en
Inventor
Deborah Hurst
Sandra Milan
Maurice J. Wolin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/293,664 external-priority patent/US20030185796A1/en
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2002362098A8 publication Critical patent/AU2002362098A8/en
Publication of AU2002362098A1 publication Critical patent/AU2002362098A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002362098A 2001-12-07 2002-12-06 Methods of therapy for non-hodgkin's lymphoma Abandoned AU2002362098A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1796801A 2001-12-07 2001-12-07
US10/017,968 2001-12-07
US10/293,664 US20030185796A1 (en) 2000-03-24 2002-11-12 Methods of therapy for non-hodgkin's lymphoma
US10/293,664 2002-11-12
PCT/US2002/039253 WO2003049694A2 (en) 2001-12-07 2002-12-06 Methods of therapy for non-hodgkin's lymphoma

Publications (2)

Publication Number Publication Date
AU2002362098A8 AU2002362098A8 (en) 2003-06-23
AU2002362098A1 true AU2002362098A1 (en) 2003-06-23

Family

ID=26690566

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002362098A Abandoned AU2002362098A1 (en) 2001-12-07 2002-12-06 Methods of therapy for non-hodgkin's lymphoma

Country Status (5)

Country Link
EP (1) EP1463524A4 (en)
JP (1) JP2005538034A (en)
AU (1) AU2002362098A1 (en)
CA (1) CA2469045A1 (en)
WO (1) WO2003049694A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572744B1 (en) 2002-12-16 2010-06-09 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2005000351A2 (en) 2003-06-05 2005-01-06 Genentech, Inc. Combination therapy for b cell disorders
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
KR20070001931A (en) * 2003-12-22 2007-01-04 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders
US20050265966A1 (en) 2004-05-20 2005-12-01 Kindsvogel Wayne R Methods of treating cancer using IL-21 and monoclonal antibody therapy
AU2005249566B2 (en) 2004-06-04 2010-11-11 Genentech, Inc. Method for treating multiple sclerosis
KR20070108402A (en) * 2005-02-15 2007-11-09 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 Methods for treating lymphomas using a combination of a chemotherapeutic agent and il-2 and optionally an anti-cd20 antibody
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
ES2618543T3 (en) 2005-11-23 2017-06-21 Genentech, Inc. Methods and compositions related to B lymphocyte assays
PT3597659T (en) 2007-07-09 2023-04-04 Genentech Inc Prevention of disulfide bond reduction during recombinant production of polypeptides
HUE030134T2 (en) 2007-10-16 2017-04-28 Zymogenetics Inc Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
ATE548052T1 (en) * 2008-01-17 2012-03-15 Philogen Spa COMBINATION OF AN ANTI-EDB-FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN AND A B-CELL-BINDING MOLECULE, B-CELL PRECURSORS AND/OR THEIR CARCINOGENIC ANTEPANT
AR073295A1 (en) 2008-09-16 2010-10-28 Genentech Inc METHODS TO TREAT PROGRESSIVE MULTIPLE SCLEROSIS. MANUFACTURING ARTICLE.
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
IL264336B2 (en) 2009-08-11 2024-02-01 Genentech Inc Production of proteins in glutamine-free cell culture media
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
PE20221007A1 (en) 2015-06-24 2022-06-15 Hoffmann La Roche ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH ENGINEERED AFFINITY
UA127887C2 (en) 2015-10-02 2024-02-07 Ф. Хоффманн-Ля Рош Аг Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
CN115369086B (en) * 2022-02-22 2023-05-12 北京景达生物科技有限公司 Culture scheme for NK cell expansion culture

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2404390A1 (en) * 2000-03-24 2001-10-04 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2

Also Published As

Publication number Publication date
EP1463524A2 (en) 2004-10-06
WO2003049694A2 (en) 2003-06-19
AU2002362098A8 (en) 2003-06-23
CA2469045A1 (en) 2003-06-19
JP2005538034A (en) 2005-12-15
EP1463524A4 (en) 2005-02-09
WO2003049694A3 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
AU2002362098A1 (en) Methods of therapy for non-hodgkin's lymphoma
AU2002257936A1 (en) Methods of well treatment
AU2001247737A1 (en) Methods of therapy for non-hodgkin's lymphoma using a combination of an antibodyto cd20 and interleuking-2
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
AU2003225160A1 (en) "biosensor for dialysis therapy"
AU2002345612A1 (en) Ultrasound-fluoroscopic seed therapy system and method
AU3891299A (en) Combination therapy for treatment of depression
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
AU3784999A (en) Methods for treatment of pain
AU2003237657A1 (en) Means and methods for improved treatment using "setrones"
AU2002256053A1 (en) Novel bgp compounds for therapy and diagnosis and methods for using same
AU5342099A (en) Dental treatment methods
AUPR731901A0 (en) Method of treatment
AU4598400A (en) Method of treatment
AU2001253560A1 (en) Methods of treatment
AU2002232563A1 (en) Compounds for therapy and diagnosis and methods for using same
AU2003286850A1 (en) ANTIGENIC gp 100 COMPOUNDS FOR THERAPY AND DIAGNOSIS AND METHODS FOR USING SAME
AU2002337442A1 (en) Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia
AU2002367463A1 (en) NOVEL p53BP2 COMPOUNDS FOR THERAPY AND DIAGNOSIS AND METHODS FOR USING SAME
AU2001255255A1 (en) Therapeutic compounds and methods
AU2002324724A1 (en) Compositions and methods for the treatment of cancer
AU2002257731A1 (en) Method of well treatment
AU2002303407A1 (en) Simplified stereotactic apparatus and methods
AU2002234506A1 (en) Method for reducing the side effects of medicaments
AUPR950401A0 (en) Methods for treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase